

Inherited Incomplete Deficiency of the Fourth Component of Complement (C4) Determined by a Gene Not Linked to Human Histocompatibility Leukocyte Antigens

W. Angus Muir, Sterling Hedrick, Chester A. Alper, Oscar D. Ratnoff, Bernice Schacter, and Jeffrey J. Wisniewski

Departments of Medicine and Pathology, Case Western Reserve University, Cleveland, Ohio 44106; Veterans Administration Medical Center, Cleveland, Ohio 46220; The Center for Blood Research and Children's Hospital Medical Center, and Department of Pediatrics, Harvard Medical School, Boston, Massachusetts 02115

Abstract. We have studied a family in which the proband had systemic lupus erythematosus and selective incomplete deficiency of the fourth component of complement (C4) (2–5% of the normal level). An additional six healthy family members also had low C4 levels (2.4–24.1% of normal) but no evidence of lupus. This form of inherited C4 deficiency differs from that in previously reported families in that inheritance was autosomal dominant (rather than recessive), C4 levels were markedly reduced (but not undetectable), and there was no linkage to HLA, BF, or C4 structural loci, all known to be within the major histocompatibility complex.

Introduction

Nine unrelated individuals have been described who lack detectable levels of the fourth component of serum complement (C4)¹ by functional and immunochemical measurements. The first patient, described by Hauptmann and co-workers (1), was an 18-yr-old girl with systemic lupus erythematosus. HLA

typing of this family suggested linkage between the C4-deficiency gene and the major histocompatibility complex (MHC) (2). Most subsequent cases of C4 deficiency (3–10) have had systemic lupus or lupuslike disease.

C4 in man is synthesized under the direction of two distinct but very closely linked loci (11), designated *C4A* and *C4B*. Half-null haplotypes containing *C4A*Q0* (quantity zero) or *C4B*Q0* are common in caucasians (12) and can best be detected in family studies by neuraminidase treatment of serum or plasma and crossed immunoelectrophoresis (13). By immunofixation of agarose gel electrophoresis of neuraminidase-treated samples, extensive structural genetic polymorphism can be recognized at both the *C4A* and *C4B* loci (14). The products of *C4A* and *C4B* differ in serological reactivity in that *C4A* variants are Rodgers positive and *C4B* variants are Chido positive (12). Under certain conditions, *C4B* has hemolytic activity whereas *C4A* does not (14). In general, *C4A* variants tend to be more acidic than *C4B* variants and the chain of *C4A* variants is of slower mobility than that of *C4B* variants on sodium dodecyl sulfate (SDS) gel electrophoresis (15).

When C4 typing was performed in a family with a child with classical C4 deficiency (16), it was shown conclusively that the deficiency resulted from homozygosity for a double-null C4 haplotype, *C4A*Q0*, *C4B*Q0*, closely linked to other loci of the MHC, including HLA. Subsequent studies have confirmed these findings (10, 17).

We have studied a 26-yr-old woman with lupus erythematosus and persistent hypocomplementemia. She appears to have a selective incomplete deficiency of C4. Her erythrocytes were positive for Rodgers and Chido antigens. 22 members of her family were studied and six relatives (of 13 at risk) were also found to have a selective deficiency of C4. HLA, BF, and C4 typing of the family did not reveal any association or

Dr. Ratnoff is a Career Investigator of the American Heart Association.

Received for publication 3 February 1984 and in revised form 18 June 1984.

1. Abbreviations used in this paper: C4, fourth component of complement; CH50, hemolytic complement; CIC, circulating immune complexes; PGM₃, phosphoglucomutase-3.

J. Clin. Invest.

© The American Society for Clinical Investigation, Inc.

0021-9738/84/10/1509/06 \$1.00

Volume 74, October 1984, 1509–1514

linkage between the gene or genes determining C4 deficiency in this family and the major histocompatibility complex.

Methods

Case study. A 26-yr-old woman was referred for evaluation of migratory polyarthritis, rash, and alopecia. Subsequently, she began to have attacks of headache, blurred vision, and scintillating scotomata. At first, headaches were associated with right, and later with left transient hemiparesis. On each occasion, cerebrospinal fluid, skull x rays, brain scans, and computed tomography were normal and her symptoms improved on high dose prednisone therapy. Antinuclear antibody was positive at 1:10 to 1:100 dilution, anti-DNA was weakly positive, and hemolytic complement (CH50) ranged from 5 to 60 units (normal = 100 ± 20 [1 SD]). Renal function was normal on repeated testing. Fibromuscular hyperplasia of the right internal carotid artery was detected by arteriography and required surgical correction. During disease activity, CH50, C3, and C4 were all decreased, whereas during periods of remission, C3 returned to normal but C4 remained at 5% of normal or less and CH50 increased but not to normal. A diagnosis of systemic lupus erythematosus was made. 22 family members from three generations were available for study. Six of these individuals were found to have reduced concentrations of C4. None had increased susceptibility to infection, a bleeding tendency, or rheumatic disease.

Fully informed consent was obtained from each individual before the collection of blood samples.

Complement assays. Blood was allowed to clot in glass tubes for 30 min at room temperature, placed at 4°C for 30 min, and then centrifuged for 5 min at 3,500 g. The separated serum was used immediately or kept frozen at -70°C until assayed. Plasma samples for measurement of C3 and C4 were drawn into Na₂EDTA, maintained at 37°C for 30 min and centrifuged and separated at 37°C before testing. CH50 titrations were performed by standard methods (18). C3 and C4 were measured by radial immunodiffusion using Hyland Laboratory, Costa Mesa, CA (C3) and Meloy Laboratory, Springfield, VA (C4) plates, respectively. Normal ranges were established in 25 healthy donors. Stoichiometric hemolytic titrations of C1, C4, and C2 were performed by the methods of Rapp and Borsos (18) and for C3 through C9 by the methods of Nelson et al. (19), as modified by Rosenfeld et al. (20). Hemolytic titrations of C1 and C4 were also performed on mixtures of normal human serum and serum from the proband drawn during a period of inactive disease. The concentrations of factor B, properdin, β -1-H, C4 binding protein, and C1 inhibitor were determined by electroimmunoassay (21). C1 inhibitor was also measured by an esterolytic assay (22) and its charge was analyzed by immunofixation after agarose gel electrophoresis. Sera were tested for circulating immune complexes (CIC) by the method of Zubler et al. (23).

Analysis of C4, BF, and HLA haplotypes. Desialated plasma samples were subjected to crossed immunoelectrophoresis for detection of null alleles at the *C4A* and *C4B* loci, as described previously (13). To detect C4 structural variants, desialated plasma samples were subjected to immunofixation electrophoresis in 0.75% agarose as previously described (14). C4 subunit size was analyzed by immunoprecipitation with anti-C4 on SDS-polyacrylamide gels (15). HLA typing for antigens at the HLA-A, B, C, and D loci was performed by a modified micromethod (24). The method for isolating B lymphocytes was according to Lowry (25). Plasma samples were subjected to agarose gel electrophoresis and immunofixation (26) with goat antiserum to human factor B (Atlantic Antibodies, Scarborough, ME) for BF typing. C2 types were determined by isoelectric focusing (27).

Additional genetic markers. Phenotypes of erythrocyte glyoxalase I (28) and white cell phosphoglucomutase-3 (PGM₃) (29) were determined by starch gel electrophoresis.

Blood clotting studies. The methods used for measurement of the platelet count, clotting time, prothrombin time, and partial thromboplastin time, and for the assay of clotting factors and inhibitors are summarized elsewhere (30, 31). The bleeding time was measured by a modification of Duke's Methods (32), and clot retraction by a semi-quantitative technique (33). Platelet retention by glass bead columns was tested by Salzman's (34) method and platelet factor 3 release by Spaet and Cintron's (35) technique. The agglutination of platelets by ristocetin, and aggregation of platelets by various agents were studied by the methods recommended by the manufacturer of Platelet Aggregation Profile, model PAP-2A (Bio/Data Corp., Hatboro, PA), adding 1:10 volume of ristocetin (15 mg/ml water, Pacific Hemostasis Lab., Bakersfield, CA), collagen 0.7 mg/ml in 0.15 M sodium chloride, (the gift of the late Dr. Howard Bensusan), adenosine diphosphate (ADP, 2×10^{-5} M in 0.15 M sodium chloride, Sigma Chemical Co., St. Louis, MO), epinephrine (10^{-4} M in 0.15 M sodium chloride, Sigma Chemical Co.), bovine thrombin (1.0 National Institutes of Health U/ml barbitalsaline buffer, Parke-Davis Co., Detroit, MI) or zymosan (6.7 mg/ml in 0.15 M sodium chloride, Sigma Chemical Co.) to 9 vol of platelet-rich citrated plasma (250,000/ μ l).

Results

The concentration of C4 in the proband's serum measured functionally over a 2-yr period was 2–5% of normal and as antigen it was 3–9% of normal. Antigenic C4 levels in EDTA plasma samples maintained at 37°C were 5–10% of normal. Table I presents the results of complement studies performed

Table I. Complement Protein Concentrations in the Patient with C4 Deficiency during Clinical Remission

Protein	Patient	Functional (F)* or Immunochemical (I)†	Normal range (M \pm 2 SD)	No. of controls
C1	186,000	F	190,000 \pm 88,000	25
C2	18,300	F	15,600 \pm 12,200	10
C3	6,600	F	8,100 \pm 5,200	7
	106	I	123 \pm 54	25
C4	4,400	F	133,000 \pm 92,000	10
	3	I	31.3 \pm 19	25
C5	44,000	F	54,800 \pm 48,000	5
C6	51,500	F	76,550 \pm 33,080	7
C7	50,600	F	80,560 \pm 54,000	5
C8	142,000	F	150,000 \pm 80,000	9
C9	80,000	F	86,000 \pm 28,000	7
P	1.3	I	1.7 \pm 1.0	9
B	25	I	18 \pm 12	25
H	75§	I	87 \pm 42	20
C4 Binding protein	42§	I	113 \pm 69	109

* Units per milliliter.

† Milligrams per deciliter.

§ % normal pooled serum.

when the proband was in complete clinical remission and taking no medication. Total hemolytic complement was moderately reduced and averaged 50% of the normal mean (100 U/ml). Admixture of the patient's serum with an equal amount of normal human serum yielded a CH50 of 50–75% of the normal mean. Normal serum mixed 1:3 and 2:3 with serum from the proband yielded C4 hemolytic activities of 40 and 100% of normal serum, respectively. The proband's serum was 75–80% as lytic (C1 activity) as normal serum against EAC4 cells. When purified C4 (Cordis Laboratories, Miami, FL) was added to the patient's serum, the CH50 increased toward normal. The serum concentrations of all complement proteins measured were normal, except for C4. In particular, C2 and C1 inhibitor were present in normal concentrations. In addition, as determined by immunofixation electrophoresis, the C4 present in the patient's serum had native electrophoretic mobility and could be typed as C4A3 QO; C4B1,2. In addition, SDS-polyacrylamide gel electrophoresis of C4 from "abnormal" family members showed subunit size that was no different from normal. This minimizes the possibility of an alteration of the C4 molecule by a major glycosylation or

Table II. Clotting Studies in a Patient with C4 Deficiency

Test or protein	Patient	Normal*
Clotting time, glass (min)	18 min	13–25 min
Clotting time, polystyrene (min)	145 min	60–245 min
Bleeding time (min)	5 min	<9 min
Thrombin time (s)	30 s	26–34 s
Prothrombin time (s)	14.5 s	14.7 s
Activated partial thromboplastin time (s)	49.9 s	34–57 s
Fibrinogen	Grossly normal	—
Fibrin-stabilizing factor (Factor XIII)	Present	—
Prothrombin (%)	100	65–150
Antihemophilic factor (Factor VIII:C) (%)	144	46–216
Hageman factor (Factor XII) (%)	56	100±28
Plasma prekallikrein (%)	114	102±23
High molecular weight kininogen (%)	70	99±26
Platelet count (per μ l)	183,000	214,000±56,000
Clot retraction (%)	60	60+
Platelet factor 3	Normal	—
Platelet retention by glass bead columns (%)	80	>25%
Platelet agglutination by ristocetin	Normal	—
Platelet aggregation by collagen, ADP, epinephrine, thrombin, and zymosan	Normal	—

* Range or mean±SD.

Table III. Protease Inhibitor Concentrations in the Patient with C4 Deficiency

Protein	Patient*	Functional (F) or Immunochemical (I)	Normal range (\bar{M} ±2 SD)
C1 inhibitor	16.2	I	110.5±66.5
	11.3‡	F	7.2±2.2
α_1 -Antitrypsin	73	I	100±53
α_2 -Macroglobulin	85	I	—
α_1 -Antichymotrypsin	73	I	—
α_2 -Antiplasmin	110	I	98±15
Antithrombin III	79	F	92±13

* Concentrations expressed as percentage of normal pooled serum.

‡ Units per ml.

Table IV. C4 and C4 Binding Protein Concentrations in Individual Family Members

Individual	C4 hemolytic activity	C4 protein	C4 binding protein
	U/ml	mg/dl	% nl pool
Members with normal values			
I-3	136,000	49	115
I-4	156,000	35	80
I-7	70,000	32	85
I-9	167,000	71	120
I-10	129,000	43	ND
II-1	78,000	19	ND
II-3	112,000	37	92
II-4	66,000	19	80
II-5	61,000	18	60
II-7	89,000	19	65
II-12	167,000	43	70
II-13	156,000	32	115
II-14	47,000	18	80
III-3	55,000	10	65
Members with hemolytic and immunochemical C4 concentrations at least 2 SD below normal			
I-5	2,800	2.5	52
I-6	29,000	12	70
II-2	20,000	6	55
II-6	32,000	7	65
II-9	27,000	6	55
II-10*	4,400	3	42
II-11	28,000	9	80
Normals (10)	133,000±92,000 (2 SD)	31.3±19 (2 SD)	

ND, not determined.

* Proband.

postsynthetic change. The electrophoretic mobility of the C₁ inhibitor in serum of the proband and all family members was normal. The concentration of C4 binding protein was decreased to 42% of normal. The patient's serum and erythrocytes were positive for Chido and Rodgers antigens.

No family members, except the proband, had clinical evidence of immune complex disease, and sera from family members were all negative for CIC (except for one). In the proband, CIC were detectable only during periods of increased lupus activity. However, decreased C4 levels in the proband were unrelated to CIC and/or level of disease activity. Low-level CIC were detected in only one family member (II-6). These were transient, and were not associated with clinical disease or decreased levels of C3 or C4. Because of the clinical abnormalities of the proband in this study, a comprehensive evaluation of hemostasis was performed (Table II). No abnormalities were detected except a reduced titer of Hageman factor (Factor XII), which was 56% of normal. Since her mother also had an intermediate titer of Hageman factor, the patient may be a heterozygote for Hageman factor deficiency.

Because the low C4 concentration in the proband's plasma might be explained by an uninhibited proteolytic attack on C4, a number of protease inhibitors were studied in the patient's plasma or serum. The concentrations of C₁ inhibitor, α_1 -antitrypsin, α_1 -antichymotrypsin, α_2 -macroglobulin, α_2 -antiplasmin, and antithrombin III were all within normal limits (Table III).

Studies in the patient's family revealed that six other members had hemolytic and immunochemical C4 concentrations below the normal range defined as the mean value ± 2 SD (Table IV). It is evident from the pedigree that the individuals with low C4 levels occurred in four subfamilies, all on the paternal side (Fig. 1). A paternal uncle (I-5) had an even lower serum C4 concentration than the proband. Of the father's three living siblings, two had C4 deficiency. One of two children of a deceased paternal uncle had C4 deficiency as did the patient's brother. Two of seven of the affected paternal uncle's children also had C4 deficiency. Thus, in this family, six of thirteen of the patient's relatives at risk, four males and two females, had C4 deficiency and there was male-to-male transmission of this trait. The pattern of inheritance is thus most likely autosomal dominant.

No evidence for linkage between C4 deficiency as a dominant trait and the MHC or other sixth chromosome markers could be obtained. In particular, there was neither linkage nor any association whatsoever between C4 genetic types and C4 deficiency. Although almost all affected individuals had one (of four) null C4 alleles and one (I-6) had two, this was also true of many family members with normal C4 levels.

Discussion

The form of C4 deficiency in the present family differs strikingly from that in previously described families (1-10) in




Figure 1. The family with C4 deficiency. Males are shown as squares, females as circles. Individuals with serum hemolytic and immunochemical C4 levels more than 2 SD below the normal mean are shown as cross-hatched symbols. The proband is indicated by an arrow. Major histocompatibility complex haplotypes are given below each symbol as a lower case letter. C4 alleles are given within parentheses in abbreviated form as C4A and C4B types with "0" for the null allele Q0. After the C4 types, BF types are given. The full haplotypes are:

a(3,1)S = HLA-A2, B40(61),Cw2,DR7,(C4A3,B1) BFS.
b(0,1)F = HLA-A2, B17(58),Cw3,DR6,(C4AQ0,B1)BFF.

c(0,2)S = HLA-A3, B27, Cw2, (C4AQ0,B2)BFS.
e(3,1)S = HLA-A28, B12(44),Cw7,DR5,(C4A3,B1) BFS.
f(3,1)S = HLA-A9(24),B40(61),Cw2,DR6,(C4A3,B1) BFS.
g(-)S = HLA-A2, B12(44), BFS.
h(3,1)S = HLA-A31, B40, Cw3, (C4A3,B1) BFS.
i(3,1)F = HLA-A24, B7, (C4A3,B1) BFF.
j(2,1)S1 = HLA-A1, Bx, (C4A2,B1) BFS.1
k(3,1)S = HLA-A2, B12, (C4A3,B1) BFF.
m(3,1)F = HLA-A1, By, (C4A3,B1) BFF.
n(0,1)S = HLA-A1, B8, (C4AQ0,B1)BFS.
o(0,2)S = HLA-A28, B40, (C4AQ0,B1)BFS.
p(0,1)S = HLA-A9(24),B13, Cw6, (C4AQ0,B1)BFS.

a number of ways. In the previous families, C4 deficiency was complete and C4 was not detectable either functionally or immunochemically. In the present family, some C4 was found in the serum of each affected individual and was present at concentrations of 2–24% of normal. Immunofixation and SDS-PAGE studies indicate that the net surface charge on the C4 molecule was as predicted from the allotypes and family studies and that no major glycosylation difference was present. In “classical” C4 deficiency, inheritance is recessive and carriers have, on average, about 50% of normal levels, although the range is so wide that serum concentration alone is a poor guide to detecting heterozygotes (3, 16) in such families. Classic C4 deficient individuals have inherited two double-null C4 haplotypes (*C4A*Q0; C4B*Q0*) (16). However, the form of C4 deficiency described here is inherited as a dominant trait, is independent of C4 structural gene types and null alleles and is not linked to the MHC or other closely associated loci of the sixth human chromosome. The present patient, like those with classical C4 deficiency, has systemic lupus erythematosus. However, the six relatives of our patient with decreased C4 have no signs of lupus or other collagen-vascular disease, suggesting that the association is by chance in this family.

Studies of the coagulation system in this family revealed only that the proband and her mother were probable heterozygotes for Hageman factor deficiency. Since there was no correlation between this abnormality and C4 levels in the family, it must be regarded as coincidental.

The only previously recognized complement deficiency state to be inherited as an autosomal dominant trait is hereditary angioneurotic edema (36) and it is associated with reduced C4 levels. Therefore, care was taken to exclude this possibility in the present family. No family member had experienced any symptoms of angioneurotic edema. C1 inhibitor serum concentrations were normal by immunochemical and functional assays and had normal electrophoretic mobility (37) in all family members. Functionally measured C2 levels were normal in all subjects. C4 was in its native state in serum from all deficient persons. These observations make it unlikely that an abnormal C1 inhibitor molecule is the cause of C4 deficiency in this family. The slightly reduced C4 binding protein concentrations in the serum of some individuals with markedly reduced C4 levels suggest C4 consumption by some uninhibited protease as the basis of the abnormality. However, the concentrations of a number of protease inhibitors such as α_1 -antitrypsin, α_1 -antichymotrypsin, α_2 -antiplasmin, antithrombin III, and α_2 -macroglobulin were normal in all sera from affected individuals.

Acknowledgments

We thank Ms. Deborah Marcus, Rosanne Stein, Cathy Ramaika, and Barbara Everson for expert technical assistance. We wish to acknowledge the great help of Marian Lewis, Rh Laboratory, University of Manitoba, Winnipeg, Canada for performing the Chido, Rodgers, and other erythrocyte antigen assays, and Dr. Eloise Giblett, Puget Sound Blood

Bank, Seattle, Washington for performing the glyoxalase, PGM₃, and other enzyme phenotyping.

This research was supported in part by a Clinical Research Center grant (RR00080) from the Division of Research Resources of the National Institutes of Health; by U. S. Public Health Service National Institutes of Health grants HL-01661, AI-14157, AM-26844, and HL-29583; and by a grant from the American Heart Association to Dr. Ratnoff.

References

- Hauptmann, G., E. Grosshans, and E. Heid. 1974. Lupus érythémateux aigus et déficits héréditaires en complément: a propos d'un cas par déficit complet en C4. *Ann. Dermatol. Syphiligr.* 101:479–496.
- Rittner, C., G. Hauptmann, H. Grosse-Wilde, E. Grosshans, M. M. Tongio, and S. Mayer. 1975. Linkage between HL-A (major histocompatibility complex) and genes controlling the synthesis of the fourth component of complement. In *Histocompatibility Testing*. F. Kissmeyer-Nielsen, editor. Munksgaard, Copenhagen. 945–954.
- Ochs, H. D., S. I. Rosenfeld, E. D. Thomas, E. R. Giblett, C. A. Alper, B. Dupont, J. G. Schaller, B. C. Gilliland, J. A. Hansen, and R. J. Wedgwood. 1977. Linkage between the gene (or genes) controlling synthesis of the fourth component of complement and the major histocompatibility complex. *N. Engl. J. Med.* 296:470–475.
- Tappeiner, G., S. Scholz, J. Linert, E. D. Albert, and K. Wolff. 1978. Hereditary deficiency of the fourth component of complement: study of a family. *Cutaneous Immunopathology. INSERM (Inst. Natl. Sante Rech. Med.) Colloq.* 80:399–404.
- Ballou, M., R. H. McLean, M. Einarson, S. Martin, E. J. Yunis, B. Dupont, and G. J. O'Neill. 1979. Hereditary C4 deficiency—genetic studies and linkage to HLA. *Transplant. Proc.* 11:1710–1712.
- Urowitz, M. B., D. D. Gladman, and J. O. Minta. 1981. Systemic lupus erythematosus in a patient with C4 deficiency. *J. Rheumatol.* 8:741–746.
- Minta, J. O., M. B. Urowitz, D. D. Gladman, T. Irizawa, and W. D. Biggar. 1981. Selective deficiency of the fourth component of complement in a patient with systemic lupus erythematosus (SLE): immunochemical and biological studies. *Clin. Exp. Immunol.* 45:72–80.
- Tappeiner, G., H. Hintner, S. Scholz, E. Albert, J. Linert, and K. Wolff. 1982. Systemic lupus erythematosus in hereditary deficiency of the fourth component of complement. *J. Am. Acad. Dermatol.* 7:66–79.
- Kjellman, M., A.-B. Laurell, B. Löw, and A. G. Sjöholm. 1982. Homozygous deficiency of C4 in a child with a lupus erythematosus syndrome. *Clin. Genet.* 22:331–339.
- Mascart-Lemone, F., G. Hauptmann, J. Goetz, J. Duchateau, G. Delespesse, B. Vray, and I. Dab. 1983. Genetic deficiency of the fourth component of complement presenting with recurrent infections and a SLE-like disease: genetical and immunological studies. *Am. J. Med.* 75:295–304.
- O'Neill, G. J., S. Y. Yang, and B. Dupont. 1978. Two HLA-linked loci controlling the fourth component of human complement. *Proc. Natl. Acad. Sci. USA.* 75:5165–69.
- O'Neill, G. J., S. Y. Yang, J. Tegoli, R. N. Berger, and B. Dupont. 1978. Chido and Rodgers blood groups are distinct antigenic components of human complement C4. *Nature (Lond.)*. 273:668–70.
- Awdeh, Z. L., D. Raum, and C. A. Alper. 1979. Genetic

polymorphism of human complement C4 and detection of heterozygotes. *Nature (Lond.)*. 282:205-207.

14. Awdeh, Z. L., and C. A. Alper. 1980. Inherited structural polymorphism of the fourth component of human complement. *Proc. Natl. Acad. Sci. USA*. 77:3576-80.

15. Roos, M. H., E. Mollenhauer, P. Démant, and C. Rittner. 1982. A molecular basis for the two locus model of human complement component C4. *Nature (Lond.)*. 298:854-56.

16. Awdeh, Z. L., H. D. Ochs, and C. A. Alper. 1981. Genetic analysis of C4 deficiency. *J. Clin. Invest.* 67:260-263.

17. Ballow, M., R. H. McLean, E. J. Yunis, Z. L. Awdeh, G. J. O'Neill, M. Einarson, and C. A. Alper. 1981. C4 polymorphism and HLA linkage: studies in a family with hereditary C4 deficiency. *Clin. Immunol. Immunopathol.* 20:354-360.

18. Rapp, H. J., and T. Borsos. 1970. Molecular basis of complement action. Appleton-Century-Crofts, New York.

19. Nelson, R. A., Jr., J. Jensen, and I. Gigli. 1966. Methods for the separation, purification and measurement of nine components of hemolytic complement in guinea-pig serum. *Immunochemistry*. 3:111-135.

20. Rosenfeld, S. I., M. E. Kelley, and J. P. Leddy. 1976. Hereditary deficiency of the fifth component of complement in man. I. Clinical, immunochemical, and family studies. *J. Clin. Invest.* 57:1626-1634.

21. Laurell, C.-B. 1966. Quantitative estimation of proteins by electrophoresis in agarose gel containing antibodies. *Anal. Biochem.* 15:45-52.

22. Pensky, J., and I. H. Lepow. 1977. Complement-related proteins. In *Methods in Immunology and Immunochemistry*. C. A. Williams, and M. Chase, editors. New York, Academic Press, 1977, IV:242-250.

23. Zubler, R. H., G. Lange, P. H. Lambert, and P. D. Miescher. 1976. Detection of immune complexes in unheated sera by a modified ¹²⁵I-C1q binding test. *J. Immunol.* 116:232-235.

24. Amos, D. B. Cytotoxicity Testing. In *NIAID Manual of Tissue Typing Techniques*. J. G. Ray, editor. N114 publication #80-545, pg 42-45, 1980.

25. Lowry, R., J. Goguen, C. B. Carpenter, T. B. Strom, and M. R. Garovoy. 1979. Improved B cell typing for HLA-DR using nylon wool column enriched B lymphocyte preparations. *Tissue Antigens*. 14:325-329.

26. Alper, C. A., T. Boenisch, and L. Watson. 1972. Genetic polymorphism in human glycine-rich beta-glycoprotein. *J. Exp. Med.* 135:68-80.

27. Alper, C. A. 1976. Inherited structural polymorphism in human C2. Evidence for genetic linkage between C2 and Bf. *J. Exp. Med.* 144:1111-1115.

28. Kompf, J., S. Bissbort, S. Gussmann, and H. Ritter. 1975. Polymorphism of red cell glyoxalase-1 (E.C.: 4.4.1.5): a new genetic marker in man: investigation of 169 mother-child combinations. *Humangenetik*. 27:141-143.

29. Goedde, H. W., and M. Stahn. 1974. PGM₃ (PGM₁, PGM₂) phenotyping in human leucocytes with a simplified method. *Human-genetik*. 22:143-145.

30. Forman, W. B., O. D. Ratnoff, and M. H. Boyer. 1968. An inherited qualitative abnormality in plasma fibrinogen. Fibrinogen Cleveland. *J. Lab. Clin. Med.* 72:455-472.

31. Ratnoff, O. D., and H. L. Nossel. Wasp sting anaphylaxis. *Blood*. In press.

32. Ratnoff, O. D., and B. Bennett. 1973. Clues to the pathogenesis of bleeding in von Willebrand's disease. *N. Engl. J. Med.* 289:1182-1183.

33. Jackson, D. P., R. C. Hartmann, and C. L. Conley. 1953. Clot retraction as a measure of platelet function. II. Clinical disorders associated with qualitative platelet defects (thrombocytopathic purpura). *Bull. Johns Hopkins Hosp.* 93:370-385.

34. Salzman, E. W. 1963. Measurement of platelet adhesiveness. A simple *in vitro* technique demonstrating an abnormality in von Willebrand's disease. *J. Lab. Clin. Med.* 62:724-735.

35. Spaet, T. H., and J. Cintron. 1965. Studies on platelet factor-3 availability. *Br. J. Haematol.* 11:269-275.

36. Donaldson, V. H., and R. R. Evans. 1963. A biochemical abnormality in hereditary angioneurotic edema: absence of serum inhibitor of C1-esterase. *Am. J. Med.* 35:37-44.

37. Rosen, F. S., C. A. Alper, J. Pensky, M. R. Klemperer, and V. H. Donaldson. 1971. Genetically determined heterogeneity of the C1 esterase inhibitor in patients with hereditary angioneurotic edema. *J. Clin. Invest.* 50:2143-2149.